A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry

Published on Aug 1, 2019in Hpb3.401
· DOI :10.1016/J.HPB.2018.12.004
Michelle M. Holland1
Estimated H-index: 1
(University of Louisville),
Neal Bhutiani13
Estimated H-index: 13
(University of Louisville)
+ 5 AuthorsRobert C.G. Martin81
Estimated H-index: 81
(University of Louisville)
Abstract Background The optimal treatment and management of locally advanced pancreatic cancer (LAPC) remains unclear and controversial. This study aimed to report the initial outcomes of the AHPBA Registry and evaluate the reproducibility of existing evidence that the addition of Irreversible Electroporation (IRE), a nonthermal ablative treatment, confers survival benefits beyond standard therapeutic options for patients with LAPC. Methods From December 2015 to October 2017, patients with LAPC were treated with open-technique IRE following the AHPBA Registry Protocols. Patient demographics, long-term outcomes, and adverse events were recorded. Survival analyses were performed using Kaplan-Meier (KM) curves for overall survival (OS), progression free survival (PFS) and time to progression (TTP). Results A total of 152 patients underwent successful IRE. Morbidity and mortality were 18% and 2% respectively, with 19 (13%) patients experiencing severe adverse events. Nine (6%) patients presented with local recurrence. Median TTP, PFS, and OS from diagnosis were 27.3 months, 22.8 months, and 30.7 months respectively. Conclusion The combination of IRE with established multiagent therapy is safe and demonstrates encouraging survival among patients with LAPC. IRE is associated with a low rate of serious adverse events and has been optimized for more widespread adoption through the standardized protocols available through the AHPBA registry.
📖 Papers frequently viewed together
18 Authors (Xiang Li, ..., Xueli Bai)
13 Citations
22 Citations
224 Citations
#1Georgios Gemenetzis (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 17
#2Vincent P. Groot (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 16
Last. Jin He (Johns Hopkins University)H-Index: 40
view all 14 authors...
Objective:The aim of the study was to identify the survival of patients with locally advanced pancreatic cancer (LAPC) and assess the effect of surgical resection after neoadjuvant therapy on patient outcomes.Background:An increasing number of LAPC patients who respond favorably to neoadjuvant thera
115 CitationsSource
#1Jantien A. VogelH-Index: 13
Last. Marc G. Besselink (AMC: Academic Medical Center)H-Index: 84
view all 14 authors...
Background Following induction chemotherapy, both resection or irreversible electroporation (IRE) may further improve survival in patients with locally advanced pancreatic cancer (LAPC). However, prospective studies combining these strategies are currently lacking, and available studies only report on subgroups that completed treatment. This study aimed to determine the applicability and outcomes of resection and IRE in patients with nonprogressive LAPC after induction chemotherapy.
56 CitationsSource
#1Hester J. SchefferH-Index: 8
Last. Martijn R. MeijerinkH-Index: 29
view all 17 authors...
Percutaneous irreversible electroporation for locally advanced pancreatic cancer is generally well tolerated, although major adverse events can occur.
80 CitationsSource
#1Robert C.G. Martin (University of Louisville)H-Index: 81
#2Alan North Durham (University of Louisville)H-Index: 1
Last. Kai-Wen Huang (NTU: National Taiwan University)H-Index: 18
view all 7 authors...
Irreversible Electroporation (IRE) is used to treat locally advanced cancers, commonly of the pancreas, liver, kidney, and other soft tissues. Precise eligibility for IRE should be established in each individual patient by a multidisciplinary team based on comprehensive clinical, imaging, and laboratory assessment. Standardization of IRE technique and protocols is expected to improve safety, lead to reproducible outcomes, and facilitate further research into IRE. The present article provides a s...
49 CitationsSource
#1Sjors KlompmakerH-Index: 13
#2T. de RooijH-Index: 5
Last. Marc G. BesselinkH-Index: 84
view all 8 authors...
Pancreatic cancer involving the coeliac axis is considered unresectable by most guidelines, with a median survival of 6-11 months. A subgroup of these patients can undergo distal pancreatectomy with coeliac axis resection, but consensus on the value of this procedure is lacking. The evidence for this procedure, including the impact of preoperative hepatic artery embolization and (neo)adjuvant therapy, was evaluated. A systematic review was performed according to the PRISMA guidelines until 27 Ma...
45 CitationsSource
#1Mustafa Suker (EUR: Erasmus University Rotterdam)H-Index: 12
#2Berend R Beumer (EUR: Erasmus University Rotterdam)H-Index: 3
Last. Bas Groot Koerkamp (EUR: Erasmus University Rotterdam)H-Index: 40
view all 20 authors...
Summary Background 35% of patients with pancreatic cancer have unresectable locally advanced disease at diagnosis. Several studies have examined systemic chemotherapy with FOLFIRINOX (leucovorin and fluorouracil plus irinotecan and oxaliplatin) in patients with locally advanced pancreatic cancer. We aimed to assess the effectiveness of FOLFIRINOX as first-line treatment in this patient population. Methods We systematically searched Embase, MEDLINE (OvidSP), Web of Science, Scopus, PubMed Publish...
432 CitationsSource
#1Michael D. Kluger (Columbia University)H-Index: 18
#2Irene Epelboym (Columbia University)H-Index: 14
Last. John A. Chabot (Columbia University)H-Index: 44
view all 8 authors...
Background Irreversible electroporation (IRE) for treatment of locally advanced pancreatic tumors is garnering increasing attention. This study was conducted to determine perioperative morbidity and mortality for locally advanced pancreatic cancer.
73 CitationsSource
#1Maria Paola Belfiore (Seconda Università degli Studi di Napoli)H-Index: 12
Last. G. BelfioreH-Index: 9
view all 9 authors...
Abstract Introduction Irreversible electroporation (IRE) is a non-thermal ablation technique recently used in pancreatic cancer. In our prospective study we evaluated safety, feasibility and efficacy of a neoadjuvant protocol based on CT-guided percutaneous IRE followed by chemotherapy in patients with locally advanced pancreatic cancer (LAPC). Methods We performed CT-guided percutaneous IRE in 20 patients with LAPC, followed by a combination of gemcitabine (1000 mg/mq) and oxaliplatin (100 mg/m...
45 CitationsSource
#1Robert C.G. Martin (University of Louisville)H-Index: 81
#2David Kwon (Cancer Treatment Centers of America)H-Index: 1
Last. Kevin Watkins (Cancer Treatment Centers of America)H-Index: 1
view all 8 authors...
Abstract Ablative therapies have been increasingly utilized in the treatment of locally advanced pancreatic cancer (LAPC). Irreversible electroporation (IRE) is an energy delivery system, effective in ablating tumors by inducing irreversible membrane destruction of cells. We aimed to demonstrate efficacy of treatment with IRE as part of multimodal treatment of LAPC. From July 2010 to October 2014, patients with radiographic stage III LAPC were treated with IRE and monitored under a multicenter, ...
239 CitationsSource
Irreversible electroporation of locally advanced pancreatic adenocarcinoma has been used to palliate appropriate patients with locally advanced pancreatic adenocarcinoma. The setting was at a university tertiary care center. Subjects are patients with locally advanced pancreatic adenocarcinoma who have undergone appropriate induction chemotherapy for at least 3 to 4 months in duration. Technique of open irreversible electroporation of locally advanced pancreatic adenocarcinoma is described. The ...
30 CitationsSource
Cited By26
Abstract null null Background null Most patients with pancreatic adenocarcinoma (PDAC) do not undergo surgical resection. The role of radiotherapy (RT) in non-operatively managed localized pancreatic adenocarcinoma is unclear. null null null Methods null The National Cancer Database (2010–2016) was queried for patients with clinical stage II-III PDAC treated with multiagent systemic chemotherapy (CT) +/− RT but not surgery. Factors associated with the receipt of RT and overall survival were comp...
#1Ulrike Heger (Heidelberg University)H-Index: 15
#2Claudia Mack (Heidelberg University)
Last. Thilo Hackert (Heidelberg University)H-Index: 57
view all 8 authors...
Abstract null null Background/objectives null Irreversible electroporation (IRE) is an emerging treatment for locally advanced pancreatic cancer (LAPC) which in some cohorts has been associated with severe complications. Additionally, re-resection of isolated local recurrence (ILR) after pancreatic ductal adenocarcinoma (PDAC) can improve survival. We investigated safety, feasibility and oncologic outcomes in the first report on open IRE for unresectable ILR of PDAC in a staged surgical approach...
1 CitationsSource
#1Govindarajan Narayanan (Baptist Hospital of Miami)
Last. Robert C.G. Martin (University of Louisville)H-Index: 81
view all 6 authors...
Irreversible electroporation (IRE) is a local ablation technique utilizing high voltage, low energy direct current to create nanopores in cell membrane which disrupt homeostasis and leads to cell death. Previous reports have suggested IRE may have a role in treating borderline resectable and unresectable Stage 3 pancreatic tumors. Patients with Stage 3 pancreatic ductal adenocarcinoma (PDAC) will be enrolled in either a randomized, controlled, multicenter trial (RCT) or a multicenter registry st...
#1Isabella FrigerioH-Index: 17
#2Salvatore PaiellaH-Index: 23
Last. G. FiorentiniH-Index: 14
view all 22 authors...
Abstract null null Background null Local ablation of pancreatic cancer has been suggested as an option to manage locally advanced pancreatic cancer (LAPC) although no robust evidence has been published to date to support its application. The aim of this study is to compare overall survival (OS) and progression-free survival (PFS) in patients receiving both radiofrequency ablation (RFA) and conventional chemoradiotherapy (CHRT) with patients receiving CHRT only. null null null Methods null This i...
#3Niels Henrik Bruun (AAU: Aalborg University)H-Index: 3
(1) Background: Irreversible electroporation (IRE) is a nonthermal ablation technique that is being studied in nonmetastatic pancreatic cancer (PC). Most published studies use imaging outcomes as an efficacy endpoint, but imaging interpretation can be difficult and has yet to be correlated with survival. The aim of this study was to examine the correlation of imaging endpoints with survival in a cohort of IRE-treated PC patients. (2) Methods: Several imaging endpoints were examined before and af...
Objectives Locally advanced pancreatic cancer (LAPC) is found in about 40% of patients with pancreatic cancer. Irreversible electroporation (IRE) is a nonthermal ablative technique that provides an alternative in patients with LAPC and can be safely combined with chemotherapy. Materials and methods From 2015 until October of 2019, we performed laparotomic IRE in a total of 40 patients with stage III LAPC. The median age of these patients was 65.2 years (range: 46 to 81 y), and the median tumor s...
BACKGROUND Most pancreatic cancer (PC) patients are incurable and may need palliative treatment at some point in time. Irreversible electroporation (IRE) is a novel ablative treatment, which aims to provide local tumor control. The aim of this study was to examine how consolidative treatment with IRE affects quality of life (QOL) and pain perception (PP) in patients with non-metastatic pancreatic cancer. METHODS Secondary outcomes were extracted from a prospective cohort of non-metastatic PC pat...
#1Chaobin He (SYSU: Sun Yat-sen University)H-Index: 11
#2Shuxin Sun (SYSU: Sun Yat-sen University)H-Index: 5
Last. Shengping Li (SYSU: Sun Yat-sen University)H-Index: 23
view all 4 authors...
Background Irreversible electroporation (IRE) is a novel treatment for locally advanced pancreatic cancer (LAPC), but the predictive factors, based on cytokines and immunocytes of survival, are still lacking. This study aimed to establish a risk model based on cytokines and immunocytes for LAPC patients undergoing IRE treatment. Patients and Methods Peripheral blood samples were obtained from 31 LAPC patients and 8 healthy control subjects before IRE. The phenotypes of lymphocytes were analyzed ...
1 CitationsSource
Locally advanced pancreatic cancer (LAPC) accounts for 30% of patients with pancreatic cancer. Irreversible electroporation (IRE) is a novel cancer treatment that may improve survival and quality of life in LAPC. This narrative review will provide a perspective on the clinical experience of pancreas IRE therapy, explore the evidence for the mode of action, assess treatment complications, and propose strategies for augmenting IRE response. A systematic search was performed using PubMed regarding ...
#1Francesco IzzoH-Index: 48
#2Vincenza GranataH-Index: 20
Last. Raffaele PalaiaH-Index: 17
view all 13 authors...
Objective. To assess local disease control rates (LDCR) and overall survival (OS) in locally advanced pancreatic cancer (LAPC) treated with electrochemotherapy (ECT). Methods. Electrochemotherapy with bleomycin was performed in 25 LAPC patients who underwent baseline Magnetic Resonance Imaging (MRI) and/or Computed Tomography (CT) and Position Emission Tomography (PET) scans before ECT and 1 and 6 months post ECT. LDCR were assessed using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)...
3 CitationsSource